Description

Tanomastat is a potent and selective synthetic inhibitor of matrix metalloproteinases (MMPs), specifically designed for research and pharmaceutical development. This compound is of significant interest for its potential role in modulating tissue remodeling and pathological processes involving extracellular matrix degradation. It serves as a critical research tool for scientists and developers in the fields of oncology, cardiology, and inflammatory diseases, where MMP activity is a key therapeutic target. The high-purity material, referenced as CAS NO 179545-77-8, is essential for ensuring reproducible and reliable experimental and developmental outcomes.

Application

• Pharmaceutical Research & Development: As a key reference standard and active pharmaceutical ingredient (API) intermediate in the development of novel anti-cancer and anti-angiogenesis therapies.
• Biochemical Assay Development: Utilized as a selective inhibitor to study the specific roles of MMP-2, MMP-9, and other gelatinases in in vitro and cell-based assay systems.
• Academic & Preclinical Studies: Employed in university and institutional labs to investigate mechanisms of tumor metastasis, atherosclerosis, rheumatoid arthritis, and other conditions involving tissue breakdown.
• Drug Discovery Screening: Serves as a positive control or benchmark compound in high-throughput screening campaigns targeting metalloproteinase activity.
• Formulation Studies: Used in stability testing and the development of drug delivery systems for potential MMP inhibitor-based therapeutics.

Basic Information

Product Name	Tanomastat
CAS No.	179545-77-8
Molecular Formula	C₂₀H₂₂N₄O₆
Molecular Weight	414.41 g/mol
Synonyms	BAY 12-9566; BAY-12-9566; BAY 129566; (S)-2-(4'-Bromobiphenyl-4-sulfonylamino)-3-methylbutyric acid 1-carbamoyl-2-methylpropyl ester; 1-[[(1S)-1-[[(4'-Bromo[1,1'-biphenyl]-4-yl)sulfonyl]amino]-2-methyl-1-oxopropyl]amino]carbonyl]-2-methylpropyl ester; MMP Inhibitor IV; MMP-2/MMP-9 Inhibitor I
EINECS	Contact for details

Quality Control

Our Tanomastat is manufactured under strict quality management systems to ensure batch-to-batch consistency and reliability for critical research applications. Each lot undergoes comprehensive analytical testing, including HPLC for purity determination, identity confirmation by spectroscopic methods (IR, NMR), and residual solvent analysis. A detailed Certificate of Analysis (COA) is provided with every shipment, documenting all critical quality attributes. We support development work requiring compliance with cGMP standards for API intermediates.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at a controlled room temperature (15-25°C). This material is hygroscopic (moisture-sensitive); therefore, the container must be kept tightly sealed in a dry environment to prevent degradation. For long-term storage, consider desiccant use and storage under an inert atmosphere.

Specification

Item	Specification
Appearance	White to off-white powder
Identification (IR)	Conforms to reference spectrum
Identification (HPLC)	Retention time corresponds to reference standard
Purity (HPLC)	≥98.0%
Related Substances (HPLC)	Individual impurity: ≤0.5% Total impurities: ≤2.0%
Water Content (KF)	≤1.0%
Residual Solvents (GC)	Complies with ICH Q3C guidelines

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.